1. Oncologic Outcomes of Laparoscopic Radical Prostatectomy: Intermediate-Term Follow- up 
Fernando P. Secin, Fernando J. Bianco, Nicholas T. Karanikolas, Karim Touijer, Bertrand Guillonneau 
European Urology Supplements 
Volume 5, Issue 19, Pages (November 2006)
DOI: /j.eursup
Copyright © 2006 European Association of Urology Terms and Conditions

2. Fig. 1
The cumulative 5-yr biochemical recurrence-free rate for 1001 patients.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

3. Fig. 2
Scatter plots of preoperative (A) and postoperative nomograms over time (B), showing that there has not been a clear stage migration or selection of patients over time.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

4. Fig. 3
Bar chart shows the proportion of patients with pT3 or pT4 disease in comparison to pT2 grouped in 100s of cases.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

5. Fig. 4
Univariate association between (A) pathologic Gleason, (B) serum prostate-specific antigen level, (C) positive surgical margin status, (D) seminal vesicle invasion, (E) lymph node status, and (F) pathologic stage and time to biochemical recurrence. The log-rank test is used to compare the Kaplan-Meier curves.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

6. Fig. 5
(A) Comparison of biochemical recurrence-free Kaplan-Meier curves between N0 and Nx disease among patients with low-risk disease, defined as prostate-specific antigen (PSA) level<10ng/ml and clinical stage T1c/T2a and biopsy Gleason score<7. (B) Comparison of the same features for patients with intermediate risk, defined by the presence of PSA level of 10–20ng/ml or clinical stage T2b or biopsy Gleason score 7.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

7. Fig. 6
Cumulative biochemical recurrence free rates of patients with extracapsular extension [ECE] (A) and/or seminal vesicle invasion [SVI] (B) with or without positive surgical margins [PSM].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions